No Data
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Huashen Technology: 2024 Annual Performance Forecast
Chengdu huasun technology group Inc., LTD. (000790.SZ): Expected loss of 8 million to -15.5 million yuan for the year 2024.
On January 21, Gelonghui reported that Chengdu huasun technology group Inc., LTD. (000790.SZ) announced the performance forecast for 2024, projecting a Net income loss attributable to Shareholders of the listed company between 8 million yuan and 15.5 million yuan, compared to a profit of 27.6595 million yuan in the same period last year; the Net income loss after deducting non-recurring gains and losses is expected to be between 10 million yuan and 19.5 million yuan, compared to a profit of 35.4214 million yuan in the same period last year. During the reporting period, the Steel structure Sector focused on high-quality projects and streamlined the scope of undertakings, resulting in a significant decrease in the output value and profit recognition for this Sector compared to last year; during the reporting period, the ongoing projects in ShanDong Lingkai are still in the trial production phase.
Chengdu Huasun Technology Group's Capsules Intended for Selection for National TCM Procurement; Shares Down 4%
Chengdu huasun technology group Inc., LTD. (000790.SZ): Sanqi Tongshu capsules are proposed to be selected for centralized volume procurement.
Gelonghui January 2, Chengdu huasun technology group Inc., LTD. (000790.SZ) announced that the company participated in the national Chinese Patent Medicine procurement alliance centralized volume purchasing work. According to the "National Chinese Patent Medicine Procurement Alliance Centralized Volume Purchasing Proposed Selected Results Announcement" released by the Hubei Medical Insurance Service Platform on December 30, 2024, the company's product Sanchi Tongshu Capsules is proposed to be selected for this centralized volume procurement.
Huashen Technology: Report for the third quarter of 2024
Some Chengdu Huasun Technology Group Inc. , LTD. (SZSE:000790) Shareholders Look For Exit As Shares Take 28% Pounding
